Edition:
India

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

6.29USD
19 Jan 2018
Change (% chg)

$0.57 (+9.97%)
Prev Close
$5.72
Open
$5.82
Day's High
$6.40
Day's Low
$5.74
Volume
879,473
Avg. Vol
314,185
52-wk High
$6.40
52-wk Low
$1.42

Select another date:

Thu, Jan 18 2018

BRIEF-Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

BRIEF-Arrowhead Pharma Announces Proposed Underwritten Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Silence Therapeutics ‍Sells Further Stake In Arrowhead Pharmaceuticals ​

* ‍SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.​

BRIEF-Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV

* ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV Source text for Eikon: Further company coverage:

BRIEF-Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT

* ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT

BRIEF-Silence Therapeutics Says Sold Further Part Of Holding In Arrowhead Pharmaceuticals Inc

* HAS SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.

BRIEF-Silence Therapeutics Says Sold Part Of Holding Of Common Shares In Arrowhead Pharmaceuticals

* THAT IT HAS SOLD PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC​

BRIEF-Silence Therapeutics Plc Reports 6.4 Pct Stake In Arrowhead Pharmaceuticals As Of Nov 29

* SILENCE THERAPEUTICS PLC REPORTS 6.4 PERCENT STAKE IN ARROWHEAD PHARMACEUTICALS INC AS OF NOVEMBER 29 - SEC FILING

BRIEF-Arrowhead Qtrly loss per share $0.07

* Qtrly revenue $9.3 million versus $39,583 Source text for Eikon: Further company coverage:

Select another date: